Investigational Cream Shows Promise for Atopic Dermatitis
Investigational Cream Shows Promise for Atopic Dermatitis
A study published in the British Journal of Dermatology indicates that an investigational nonsteroidal topical cream, called PAC-14028, may be effective for treating atopic dermatitis.
The trial involved a cream that blocks the transient receptor potential vanilloid subfamily, member 1, an ion channel involved in the perception of pain. This channel also contributes to inflammation and itchy skin in patients with atopic dermatitis.
For the phase 2b study, 194 patients with mild‐to‐moderate atopic dermatitis were randomised to receive PAC‐14028 cream 0.1%, 0.3%, 1.0% or vehicle cream twice daily.
The primary endpoint was the Investigator's Global Assessment (IGA) success rate, defined as the percentage of patients with an IGA score of 0 or 1 at week 8. Secondary outcomes included the severity Scoring of Atopic Dermatitis (SCORAD) index and Eczema Area and Severity Index (EASI) 75/90.
At week 8, the IGA success rates were 14.58% for vehicle cream, 42.55% for PAC‐14028 cream 0.1% (P = .0025 vs vehicle), 38.30% for PAC‐14028 cream 0.3% (P = .0087 vs vehicle) and 57.45% for PAC‐14028 cream 1.0% (P< .001 vs vehicle).
The SCORAD index, EASI 75/90, sleep disturbance score and pruritus visual analogue scale showed a trend towards improvement. No significant safety issues were reported.
"PAC‐14028 cream is a promising new treatment option for patients with mild‐to‐moderate atopic dermatitis," wrote Miyoung Park, MD, Vital Beautie Research Institute, AmorePacific Corporation R&D Center, Yongin, Republic of Korea, and colleagues. "Based on these results, a phase 3 programme is underway to assess the efficacy and safety of PAC‐14028 topical cream in adolescent and adult patients with mild‐to‐moderate atopic dermatitis.
Reference: https://doi.org/10.1111/bjd.17455
SOURCE: Wiley
posted by dermatica at
January 17, 2019
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home